Barriers to non-small cell lung cancer trial eligibility

Jeffrey J. Hardesty a,b, Norma F. Kanarek c,d,e,∗

a Johns Hopkins University Bloomberg School of Public Health, USA
b Johns Hopkins University School of Medicine, Geriatrics Department, USA
c Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, USA

d Johns Hopkins University School of Public Health, USA

ARTICLE INFO
Keywords:
Lung cancer
Trials
Eligibility
Barriers

ABSTRACT
Introduction: Cancer clinical trial (CCT) enrollment is low potentially threatening the generalizability of trial results and expedited regulatory approvals. We assessed whether type of initial patient appointment for non-small cell lung cancer (NSCLC) is associated with CCT eligibility.

Methods: Using a patient-to-accrual framework, we conducted a quasi-retrospective cohort pilot study at Sidney Kimmel Comprehensive Cancer Center (SKCCC), Baltimore, Maryland. 153 NSCLC patients new to SKCCC were categorized based on type of initial appointment: patients diagnosed or treated and patients seen for a consultation. CCT eligibility was determined by comparing eligibility criteria for each open trial to the electronic medical record (EMR) of each patient at every office visit occurring within 6-months of initial visit.

Results: We found no association between type of initial appointment and CCT eligibility (OR, 1.15; 95% CI, 0.49–2.73). Analyses did suggest current smokers were less likely to be eligible for trials compared to never smokers (OR, 0.15; 95% CI, 0.03–0.64), and stage 4 patients with second line therapy or greater were more likely to be eligible than stage 1 or 2 patients (OR, 5.18; 95% CI, 1.08–24.75). Additional analyses suggested most current smokers and stage 1 or 2 patients had trials available but were still ineligible.

Conclusions: SKCCC has a diverse portfolio of trials available for NSCLC patients and should consider research strategies to re-examine eligibility criteria for future trials to ensure increased enrollment of current smokers and stage 1 or 2 patients. We could not confirm whether type of initial visit was related to eligibility.

1. Introduction

Cancer clinical trial (CCT) enrollment has been low for decades and is a central issue in oncology because the profile of trial participants does not match the diversity found in treatment populations. CCTs differentially exclude minorities, female, and older patients threatening the generalizability of trial results and expedited regulatory approvals [1,2].

Patient-, physician-, and protocol-centered factors are known to affect CCT enrollment [3]. A patient’s willingness to enroll may depend on travel distance, treatment options, internet access, income, trust, and patient preferences [4–10]. Known physician-centered factors include incompatibility of protocols with normal practice, lack of compliance with protocols, consent procedures, discussion of trials, timing of trial information presentation, and time constraints [9,11,12]. Protocol-centered factors include limited trial availability and potentially overly restrictive eligibility criteria (e.g., prior cancer in early-stage or stage 4 lung cancer patients) [2,3,13–15].

Previous interventions to remove barriers to CCT enrollment have focused on physician- and patient-centered factors, like trial education and navigation systems [16–18]. In practice, intervention benefits have been limited suggesting protocol-centered or more comprehensive interventions should be considered [16–21]. For example, Ohio State University Comprehensive Cancer Center (OSUCCC) increased CCT enrollment 40% within two years by increasing oversight of the CCT process; educating stakeholders (e.g., patients, physicians, staff, leadership, etc.); ensuring CCTs are available irrespective of cancer type and stage of disease; and improving trial enrollment operations and infrastructure [20].

Building on the OSUCCC campaign, patient-to-accrual frameworks that address patient-, physician-, and protocol-centered factors have the potential to identify barriers and increase enrollment through subsequent interventions [20,22]. According to one established framework, there are seven steps to enrollment [1]: trials must be available for a patient’s cancer type, stage, and line of therapy [2], patient must be eligible for the trial(s) [3], physician must not triage the patient [4], physician must discuss the trial with the patient [5], patient must be interested [6], patient must sign a consent form, and [7] patient must...
pass the final screen and enroll in the trial. Each step is conditional on the previous step [22]. Therefore trial availability and eligibility are upstream steps and potential barriers to enrollment that would require institution- or protocol-specific interventions.

Lung cancer is the number one cause of cancer-related death in the U.S. making it a research priority across the country, and, like other CCTs, enrollment is low [1,23]. Given that National Cancer Institute (NCI) sponsored CCTs are listed online to help cancer patients determine their eligibility prior to seeking care, our primary goal was to assess whether type of initial appointment was related to CCT eligibility among a sample of non-small cell lung cancer (NSCLC) patients seen at Sidney Kimmel Comprehensive Cancer Center (SKCCC) [24,25]. We hypothesized consult patients would have higher odds of eligibility compared to patients seen for a diagnosis or treatment because savvy patients may self-navigate to trials they believe they are eligible for [26]. Secondary goals included assessing whether type of initial appointment or other factors were related to trial availability or eligibility conditional upon an available trial.

2. Materials and methods

2.1. Study design

A quasi-retrospective cohort design was used to investigate whether the type of initial appointment was related to trial eligibility at SKCCC. We examined each patient’s electronic medical record (EMR) longitudinally for six months to determine trial availability and eligibility for each trial at every appointment. The date that eligibility screenings occurred in clinic was not recorded due to an assumption that each appointment was an opportunity to screen patients for eligibility.

The Johns Hopkins School of Medicine Institutional Review Board approved this study.

2.2. Study population

NSCLC patients seen for their first appointment at a Baltimore-area NCI comprehensive cancer center from July 2012 through January 2013 were identified in the EMR as new patients (n = 153). Each patient was followed in the EMR until they became eligible for a trial or they were administratively censored 6 months after their initial visit.

2.3. Independent variables

The independent variable was type of initial appointment, which was dichotomized: those seeking diagnosis or treatment at the initial appointment and those seeking a consult but no diagnosis or treatment at the initial appointment. The Johns Hopkins Hospital cancer registry categorized each study patient.

Administrative staff at SKCCC recorded patients’ smoking status (never, former, or current) and demographic data before the patients’ initial visit. Patient demographics included: age at time of initial visit, sex (male or female), and race (white, black, or other races). It is presumed the patients self-reported their race. Each variable was abstracted from the EMR by one of the investigators (JH).

2.4. Outcomes

The primary outcome was clinical trial eligibility. Eligibility was determined by comparing eligibility criteria for each open trial with the EMR of each patient at each appointment until they were eligible for a trial or 6 months from their initial visit had passed.

Secondary outcomes were trial availability and trial eligibility conditional on trial availability. Both were ascertained using the seven-step framework for CCT enrollment [7]. More specifically, trial availability was determined by crosschecking each patient’s NSCLC stage-and-line of therapy with a list of available trials at each appointment.

Lists of available trials were provided for two time points (June 2012 and June 2013). Only patients with available trials were examined further for trial eligibility per the same abstraction protocol as the primary outcome.

2.5. Statistical analysis

One NSCLC patient new to SKCCC had missing demographic values and was dropped from the data set after substantial efforts to locate the missing values were unsuccessful. Dropping one patient was not expected to influence the results. One hundred fifty-three NSCLC patients were included in the analyses.

Before testing our primary hypothesis, we identified covariates and potential confounders. The literature suggested age, sex, and race were related to enrollment but was less conclusive regarding smoking status and cancer stage-and-line of therapy [1]. Thus smoking status and stage-and-line of therapy were considered two potential confounders. Chi-square analyses were conducted to help identify relationships between these variables and our main exposure, appointment type, and our primary outcome, eligibility (Tables 1 and 2, respectively).

To test our primary hypothesis we created a multiple logistic regression model using the backwards selection method. Three separate models derived from the backwards selection were also compared using Akaike information criterion (AIC). The final model included the independent variable and all covariates and confounders: type of initial appointment and all covariates and confounders: type of initial appointment. Each model was evaluated using a likelihood ratio test [4].

To further examine the upstream steps or barriers to enrollment, we tested the relationships between type of initial appointment and trial availability and eligibility conditional on trial availability using chi-square analyses. Associations between significant confounders and secondary outcomes were also analyzed by chi-square analyses.

### Table 1

Baseline characteristics of NSCLC patients new to SKCCC.

| Characteristic | Diagnosis or treatment (n = 153) | Consult only (n = 86) | Total (n = 153) | P value |
|---------------|---------------------------------|----------------------|----------------|---------|
| Age, y        |                                 |                      |                |
| < 60          | 26 (36.8)                       | 30 (35.8)            | 56 (36.6)      | 0.48    |
| 60-69         | 21 (31.3)                       | 24 (27.9)            | 45 (28.6)      |         |
| > = 70        | 20 (29.9)                       | 21 (24.4)            | 41 (26.8)      |         |
| Sex, %        |                                 |                      |                |
| Female        | 32 (47.8)                       | 44 (51.2)            | 76 (49.7)      | 0.68    |
| Male          | 35 (52.2)                       | 42 (48.9)            | 77 (50.3)      |         |
| Race          |                                 |                      |                |
| White         | 46 (68.7)                       | 63 (73.3)            | 109 (71.2)     | 0.13    |
| Black         | 16 (23.9)                       | 11 (12.8)            | 27 (17.6)      |         |
| Other         | 5 (7.5)                         | 12 (14.0)            | 17 (11.1)      |         |
| Smoking status|                                 |                      |                |
| Never         | 33 (49.3)                       | 52 (60.5)            | 85 (55.6)      | 0.05    |
| Former        | 18 (26.9)                       | 10 (11.6)            | 28 (18.3)      | < 0.001 |
| Current       |                                 |                      |                |
| Stage and line of treatment | 11 (16.4) | 4 (4.7) | 15 (9.8) |         |
| Stage 1 or 2  | 16 (23.9)                       | 11 (12.8)            | 27 (17.6)      |         |
| Stage 3       | 30 (44.8)                       | 25 (29.1)            | 55 (35.9)      |         |
| Stage 4: first line therapy | 10 (14.9) | 10 (11.6) | 56 (36.6) |         |
| Stage 4: second line therapy or greater | | | | |
| Eligibility   |                                 |                      |                |
| Eligible      | 41 (61.2)                       | 36 (41.9)            | 77 (50.3)      | 0.18    |
| Ineligible    | 26 (38.8)                       | 50 (58.1)            | 76 (49.7)      |         |

*Note: lists of available trials were provided for two time points (June 2012 and June 2013). Only patients with available trials were examined further for trial eligibility per the same abstraction protocol as the primary outcome.*
### 3. Results

#### 3.1. Study participants and baseline characteristics

There were 834 oncology patients screened for inclusion into our study. 681 of which were excluded because they did not have NSCLC, had an appointment prior to our study start date, or were missing demographic data. The primary analysis was conducted on 153 NSCLC patients new to SKCCC with an average age of 64.0 years (SD, 10.3 years).

Of the 153 patients, 67 (43.8%) were diagnosed or scheduled for treatment at their first visit and 86 (56.2%) were not diagnosed or scheduled for treatment at their first visit because they were at the clinic for a consult only. Patients categorized by type of initial appointment differed significantly by smoking status and cancer stage-and-line of therapy (p = 0.05 and p < 0.001, respectively) (Table 1).

#### 3.2. Covariates and potential confounders

Previous studies have found that age, sex, and race are related to patient comorbidities and clinical trial enrollment [9]. Therefore we adjusted for these covariates in our examination of the hypothesis. According to the chi-square analyses, smoking status and stage-and-line of therapy were related to the independent variable and the primary outcome supporting the notion they confound the relationship between initial appointment type and eligibility (Tables 1 and 2). Further investigation of these relationships were carried out in the model-building portion of our analysis.

#### 3.3. Logistic regression

Multiple logistic regression was used to assess the relationship between type of initial appointment and eligibility, and the final model was built using the backwards selection method. The final logistic regression model examined eligibility as function of type of initial appointment, age, sex, race, smoking status, and stage-and-line of therapy and suggested both smoking status and stage-and-line of therapy were confounders.

Three models were derived from the backwards selection. The full model contained six variables; another contained all variables except for smoking status; and the last model contained all variables except for stage-and-line of therapy. The AIC results confirmed that the full model contained the least variation attributed to error and was the best overall fit.

#### 3.4. Types of initial appointment and eligibility

After adjusting for the covariates and confounders, there was no statistically significant relationship between type of initial appointment and trial eligibility (Odds Ratio [OR], 1.32; 95% Confidence Interval [CI], 0.57–3.07) (Table 3). Stage 4 NSCLC patients receiving 1st line therapy appear 4.43 times more likely than stage 1 or 2 patients to be eligible for trials (OR, 4.43; 95% CI, 0.99 to 19.94). Stage 4 patients receiving 2nd line therapy or greater were 5.18 times more likely than stage 1 or 2 patients to be eligible for trials (OR, 5.18; 95% CI, 1.08 to 24.75).

#### 3.5. Other variables and eligibility

Despite failing to reject the null hypothesis, we discovered other potentially important associations that merit attention. Current smokers, for instance, appear to be far less likely to be eligible for trials than never smokers after adjustment (OR, 0.15; 95% CI, 0.03–0.64) (Table 3). Stage 4 NSCLC patients receiving 1st line therapy appear 4.43 times more likely than stage 1 or 2 patients to be eligible for trials (OR, 4.43; 95% CI, 0.99 to 19.94). Stage 4 patients receiving 2nd line therapy or greater were 5.18 times more likely than stage 1 or 2 patients to be eligible for trials (OR, 5.18; 95% CI, 1.08 to 24.75).

### Table 2
Baseline characteristics of NSCLC patients new to SKCCC.

| Characteristic          | Ineligible for trials (n = 77) | Eligible for trials (n = 76) | Total (n = 153) | P value |
|-------------------------|--------------------------------|------------------------------|-----------------|---------|
| Age, y                  |                                |                              |                 |         |
| < 60                    | 25 (32.5)                      | 31 (40.8)                    | 56 (36.6)       | 0.40    |
| 60–69                   | 28 (36.4)                      | 28 (36.8)                    | 56 (36.6)       |         |
| > 70                    | 24 (31.2)                      | 17 (22.4)                    | 41 (26.8)       |         |
| Sex, %                  |                                |                              |                 |         |
| Male                    | 34 (44.2)                      | 43 (56.6)                    | 77 (50.3)       | 0.12    |
| Female                  | 36 (46.8)                      | 23 (30.3)                    | 59 (39.7)       | 0.12    |
| Race                    |                                |                              |                 |         |
| White                   | 18 (23.4)                      | 9 (11.8)                     | 27 (17.6)       | 0.15    |
| Black                   | 9 (11.7)                       | 8 (10.5)                     | 17 (11.1)       |         |
| Smoking status          |                                |                              |                 | < 0.0001|
| Never                   | 36 (46.8)                      | 49 (64.5)                    | 85 (55.6)       |         |
| Former                  | 24 (31.2)                      | 4 (5.3)                      | 28 (18.3)       |         |
| Stage and line of treatment |                          |                              |                 |         |
| Stage 1 or 2            | 23 (29.9)                      | 32 (42.1)                    | 55 (35.9)       |         |
| Stage 3                 | 18 (23.4)                      | 38 (50.0)                    | 56 (36.4)       |         |
| Stage 4: first line therapy |                          |                              |                 |         |
| Stage 4: second line therapy or greater | |                              |                 |         |
| Type of initial appointment |                        |                              |                 |         |
| Consult only            | 41 (53.3)                      | 26 (34.2)                    | 67 (43.8)       | 0.02    |
| Diagnosis or treatment  | 36 (46.8)                      | 50 (65.8)                    | 86 (56.2)       |         |

### Table 3
Results of multiple logistic regression analyses: Eligibility for NSCLC clinical trials.

| Covariates                        | OR (95% CI) | P value |
|-----------------------------------|-------------|---------|
| Age, y                            | ref         | ref     |
| < 60                              | 0.66 (0.26–1.63) | 0.36    |
| 60–69                             | 0.56 (0.20–1.51) | 0.25    |
| > 70                              | ref         | ref     |
| Sex, %                            | ref         | ref     |
| Male                              | 1.44 (0.63–3.32) | 0.39    |
| Female                            | ref         | ref     |
| Race                              | ref         | ref     |
| White                             | 0.67 (0.22–2.06) | 0.49    |
| Black                             | 0.48 (0.13–1.79) | 0.27    |
| Smoking status                    | ref         | ref     |
| Never                             | 0.85 (0.29–2.48) | 0.77    |
| Former                            | 0.15 (0.03–0.64) | 0.01    |
| Current                           | ref         | ref     |
| Stage and line of treatment       | ref         | ref     |
| Stage 1 or 2                      | 0.36 (0.06–2.30) | 0.28    |
| Stage 3                           | 4.43 (0.99–19.94) | 0.05    |
| Stage 4: first line therapy       | 5.18 (1.08–24.75) | 0.04    |
| Stage 4: second line therapy or greater | 1.32 (0.57–3.07) | 0.51    |

Wald Test: Age (p = 0.47), Race (p = 0.44), Smoking status (p = 0.02), and Stage-and-line of treatment (p < 0.0001).
and trial availability (p < 0.0001 and p = 0.01, respectively). It also
the variables, stage-and-line of therapy and type of initial appointment,
were eligible for a trial.

(100%) had an available trial, but only 3 (20%) with an available trial
However we did
appointment and eligibility for NSCLC clinical trials after adjustment.

4. Discussion

We found no evidence of an association between type of initial
appointment and eligibility for NSCLC clinical trials after adjustment.
However we did find the odds of eligibility were 85% lower for current
smokers compared to never smokers, and the odds of eligibility were
343% greater for patients with stage 4–1st line therapy and 418%
greater for patients with stage 4–2nd line therapy or greater compared
to stage 1 or 2 patients.

Upstream steps to trial enrollment, like eligibility, have the poten-
tial to limit the overall number of patients and to protect research
subjects from unnecessary harm. The key is maintaining an ethical
balance that translates to generalizable and safe NSCLC research [2,22].
In addition, Beaver et al., 2017 correctly states, “the Food and Drug
Administration (FDA) regulations state that a ‘protocol is required to
contain … the criteria for patient selection and for exclusion of patients’
but do not contain detailed language regarding clinical trial eligibility
criteria. Regulatory approval, however, must be predicated on data
pertinent to the enrolled patients and relevant to the U.S. population
and U.S. medical practice.” Ethically conducted interventions based on
eligibility criteria have the potential to increase CCT enrollment, ad-
dress generalizability issues, and safely expedite FDA approval of pre-
scribing information [2]. It is therefore important to carefully describe
the ineligible CCT populations; investigate the reason(s) they are not
eligible; conduct studies to determine whether the criteria can be eased
in future clinical trials without harming participants; and disseminate
the results to principal investigators and Institutional Review Boards
[2,13,14].

In this particular pilot study, current smokers and stage 1 or 2 pa-
tients had trials available but were disproportionately ineligible for
trials. Current smokers may have been disproportionately ineligible due
to poorer performance status, more severe comorbidities, previous
therapies, recent NSCLC diagnosis, or a number of other trial-specific
reasons. Stage 1 or 2 patients were likely disproportionately ineligible
due to past medical history (i.e., previous case of cancer), previous
treatment, or tumor size-based inclusion criteria. A more thorough in-
vestigation at SKCCC is needed, but it is possible that criteria, such as
prior cases of cancer, may be unnecessarily restricting clinical trial
enrollment at SKCCC. For instance, previous studies have found that
patients with prior cases of cancer represent a sizeable proportion of
cancer patients yet prior cases of cancer do not increase risks for clinical
trial participants. Therefore we believe that future studies should aim
to: prospectively identify criteria causing current smokers and stage 1
or 2 to be excluded at the eligibility step of enrollment; identify po-
tentially modifiable eligibility criteria; test whether it is safe to modify
the criteria; and monitor future enrollment after implementation of the
modified criteria [2,13,14].

To our knowledge, this is the only study that has examined the re-
lationship between type of initial appointment and NSCLC-specific trial
eligibility. All variables were abstracted twice to verify accuracy. The
primary outcome was abstracted by crosschecking all verifiable elig-
ibility criteria for each open trial to each patient’s EMR. The outcome
abstraction was repeated at every office visit during the study period to
more accurately reflect the enrollment process and avoid visit-related
biases.

We acknowledge several important limitations. This was a pilot
study with a small sample size, which increased the probability of
finding significant associations by chance alone. The chart review was
conducted at a single comprehensive cancer center limiting the external
validity. For practical reasons, the study was retrospective preventing
us from controlling the study conditions. The list of available trials may
not have been comprehensive because it was not possible to know ex-
actly when new trials were added and old trials removed. Finally, re-
sidual confounding cannot be ruled out because variables, such as
distance to SKCCC and phase of clinical trials, were not abstracted.

5. Conclusions

The SKCCC has a diverse portfolio of trials available for NSCLC
patients but should consider using research strategies to re-examine
eligibility criteria for future trials to ensure more inclusive enrollment
of current smokers and stage 1 or 2 patients. Future research should
prospectively identify criteria causing current smokers and stage 1 or 2

Table 4

| Characteristic                        | Not available (n = 13) | Available (n = 140) | P value | Available but not eligible (n = 64) | Available and eligible (n = 76) | P value |
|--------------------------------------|-----------------------|--------------------|---------|-----------------------------------|-------------------------------|---------|
| Smoking status                       | 0 (0.0)               | 40 (28.6)          | 0.08    | 17 (26.6)                         | 23 (30.3)                    | < 0.0001|
| Never                                | 10 (76.9)             | 75 (53.6)          |         | 26 (40.6)                         | 49 (64.5)                    |         |
| Former                               | 3 (23.1)              | 25 (17.9)          |         | 21 (32.8)                         | 4 (5.3)                      |         |
| Current                              |                       |                    |         |                                   |                               |         |
| Stage and line of treatment          |                       |                    |         |                                   |                               |         |
| Stage 1 or 2                         | 0 (0.0)               | 15 (10.7)          | < 0.0001| 12 (18.8)                         | 3 (4.0)                      | < 0.0001|
| Stage 3                              | 12 (92.3)             | 15 (10.7)          |         | 12 (18.8)                         | 3 (4.0)                      |         |
| Stage 4: First line therapy          | 1 (7.7)               | 54 (38.6)          |         | 22 (34.4)                         | 32 (42.1)                    |         |
| Stage 4: Second line therapy or      | 0 (0.0)               | 56 (40.0)          |         | 18 (28.1)                         | 38 (50.0)                    |         |
| greater                              |                       |                    |         |                                   |                               |         |
| Type of initial appointment          |                       |                    |         |                                   |                               |         |
| Diagnosis or treatment               | 10 (76.9)             | 57 (40.7)          | 0.012   | 31 (48.4)                         | 26 (34.2)                    | 0.09    |
| Consult only                         | 3 (23.1)              | 83 (59.3)          |         | 33 (51.6)                         | 50 (65.8)                    |         |

3.6. Upstream associations examined further

To this point, we have focused on trial eligibility. In the following
analyses, we examined the relationship between our independent
variables and trial availability and the relationship between in-
dependent variables and trial eligibility conditional on trial availability
[7]. Relationships between the variables, smoking status and stage-and-
line of therapy, and the secondary outcomes were also assessed. The
main purpose for conducting these analyses was to better understand
the upstream effects preventing certain patients from moving past the
eligibility phase of the enrollment process.

Our study population contained 28 current smokers. Of these, 25
(89%) had an available trial. Only 4 (16%) with an available trial were
eligible for a CCT (Table 4). Out of the 15 stage 1 or 2 patients, 15
(100%) had an available trial, but only 3 (20%) with an available trial
were eligible for a trial.

The chi-square analyses suggested unadjusted relationships between
the variables, stage-and-line of therapy and type of initial appointment,
and trial availability (p < 0.0001 and p = 0.01, respectively). It also
suggested significant unadjusted relationships between the variables,
smoking status and stage-and-line of therapy, and eligibility
(p < 0.0001 and p < 0.0001, respectively).
to be excluded at the eligibility step of enrollment; identify potentially modifiable eligibility criteria; test whether it is safe to modify the criteria; and monitor future enrollment after implementation of the modified criteria.

6. Conflicts of interest and source of funding

This work was supported in part by the Maryland Cigarette Restitution Fund at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Support Grant from the National Cancer Institute (P30 CA006973), and the Medical Students Training in Aging Research Program (T35AG026758). Funders did not influence study design, data collection, analysis, interpretation of data, writing of the manuscript, or the decision to submit for publication.

Disclaimers

The views expressed in the article are those of the authors only and are not an official position of the institutions or funders.

Acknowledgements

We thank Dina Lansey, MSN, RN, OCN and Dr. Michael Carducci, MD, Johns Hopkins School of Medicine, for their helpful advice on the study concept and design. Additionally, we thank Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine, and Sidney Kimmel Comprehensive Cancer Center for their support of this research.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.conctc.2017.11.010.

References

[1] V.H. Murthy, H.M. Krumholz, G.P. Gross, Participation in cancer clinical trials: race, sex, and age-based disparities, JAMA J. Am. Med. Assoc. 291 (22) (2004) 2720.
[2] J.A. Beaver, G. Ison, R. Pazdur, Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials, N. Engl. J. Med. 367 (16) (2017) 1504.
[3] E.J. Mills, D. Seely, B. Rachlis, et al., Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors, Lancet Oncol. 7 (2) (2006) 141.
[4] N.F. Kanarek, H.L. Tsai, S. Metzger-Gaud, et al., Geographic proximity and racial disparities in cancer clinical trial participation, J. Natl. Compr. Cancer Netw. 8 (12) (2010) 1343.
[5] W.B. Satteren, E.L. Trimble, J. Abrams, et al., How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials, J. Clin. Oncol. 20 (8) (2002) 2109.
[6] V.L. Shavers, C.F. Lynch, L.F. Burmeister, Racial differences in factors that influence the willingness to participate in medical research studies, Ann. Epidemiol. 12 (4) (2002) 248.
[7] C. Simon, S. Schramm, S. Hillis, Patient internet use surrounding cancer clinical trials: clinician perceptions and responses, Contemp. Clin. Trials 31 (3) (2010) 229.
[8] J.M. Unger, J.R. Gralow, K.S. Albain, S.D. Ramsey, D.L. Hershman, Patient income level and cancer clinical trial participation: a prospective survey study, JAMA Oncol. 2 (3) (2016) 137.
[9] L. Mc Grath-Lone, S. Day, C. Schoenborn, H. Ward, Exploring research participation among cancer patients: analysis of a national survey and an in-depth interview study, BMC Cancer 15 (1) (2015) 1.
[10] M.M. Byrne, S.L. Tannenbaum, S. Glück, J. Hurley, M. Antoni, Participation in cancer clinical trials: why are patients not participating? Med. Decis. Mak. 34 (1) (2014) 116.
[11] C. Tournoux, S. Katsahian, S. Chevret, V. Levy, Factors influencing inclusion of patients with malignancies in clinical trials, Cancer 106 (2) (2006) 258.
[12] J.K. Logan, C. Tang, Z. Liao, et al., Analysis of factors affecting successful clinical trial enrollment in the context of three prospective, randomized controlled trials, Int. J. Radiat. Oncol. Biol. Phys. 97 (4) (2017) 770.
[13] S.L. Pruitt, A.L. Laccetti, L. Xuan, E.A. Halm, D.E. Gerber, Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer, Br. J. Cancer 116 (6) (2017) 717.
[14] A.L. Laccetti, S.L. Pruitt, L. Xuan, E.A. Halm, D.E. Gerber, Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual, J. Natl. Cancer Inst. (4) (2015) 107.
[15] J. Rearden, A.L. Hanlon, C. Ulrich, M. Brooks-Carthon, M. Sommers, Examining differences in opportunity and eligibility for cancer clinical trial participation based on sociodemographic and disease characteristics, Oncol. Nurs. Forum 43 (1) (2016) 57.
[16] G.G. Kimmick, B.L. Peterson, A.B. Kombliith, et al., Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001, J. Clin. Oncol. 23 (10) (2005) 2201.
[17] K. Moffitt, F. Brogan, C. Brown, et al., Statewide cancer clinical trial navigation service, J. Oncol. Pract. 6 (3) (2010) 127–132.
[18] A.M. Denicoff, W. McCaskill-Stevens, S.S. Grubbs, et al., The national cancer institute-american society of clinical oncology cancer trial accrual symposium: summary and recommendations, J. Oncol. Pract. 9 (6) (2013) 267.
[19] E.D. Paskett, K.W. Reeves, J.M. McLaughlin, et al., Recruitment of minority and underserved populations in the United States: the centers for population health and health disparities experience, Contemp. Clin. Trials 29 (6) (2008) 847.
[20] M. Porter, B. Ramaswamy, K. Beisler, et al., A comprehensive program for the enhancement of accrual to clinical trials, Ann. Surg. Oncol. 23 (7) (2016) 2146.
[21] D.R. Holmes, J. Major, D.E. Lyonga, R.S. Alleyne, S.M. Clayton, Increasing minority patient participation in cancer clinical trials using oncology nurse navigation, Am. J. Surg. 203 (4) (2012) 415.
[22] N.F. Kanarek, M.S. Kanarek, D. Olatove, M.A. Carducci, Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart re- view study, Trials 13 (1) (2012) 257.
[23] F. Brogan, C. Brown, J.A. Beaver, B. Rachlis, et al., Differences in factors that influence successful clinical trial participation based on sociodemographic and disease characteristics, Oncol. Nurs. Forum 43 (1) (2016) 132.
[24] Center for Disease Control and Prevention, Lung Cancer. Lung Cancer Web Site, (2014) http://www.cdc.gov/cancer/lung/ , Accessed date: 23 April 2015Updated.
[25] National Institutes of Health, National Cancer Institute, Office of Communications. Cancer Clinical Treatment Trials: Informational Preferences of Patients and Their FamiliesNCCIC, (1996).
[26] Find NCI-supported Clinical Trials - National Cancer Institute, (2017) https://www.cancer.gov/about-cancer/treatment/clinical-trials/search , Accessed date: 27 June 2017.
[27] National Cancer Institute. Clinical Trials, (2015) http://www.cancer.gov/clinicaltrials Updated.